These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31673229)

  • 21. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avatrombopag for the salvage treatment of platelet transfusion refractoriness.
    Qin Y; Wang Y; Zhang Y; Jiao Y; Ye J
    Ther Adv Hematol; 2024; 15():20406207241237606. PubMed ID: 38481948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia.
    Eguchi Y; Takahashi H; Mappa S; Santagostino E
    Hepatol Res; 2022 Apr; 52(4):371-380. PubMed ID: 35134259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
    Olson SR; Koprowski S; Hum J; McCarty OJT; DeLoughery TG; Shatzel JJ
    Platelets; 2019; 30(6):796-798. PubMed ID: 30422039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avatrombopag: First Global Approval.
    Shirley M
    Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
    Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
    Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
    Maan R; de Knegt RJ; Veldt BJ
    Drugs; 2015 Nov; 75(17):1981-92. PubMed ID: 26501978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
    Tsykunova G; Ghanima W
    Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetic/Pharmacodynamic Analyses of Avatrombopag in Patients With Chronic Liver Disease and Optimal Dose Adjustment Guide With Concomitantly Administered CYP3A and CYP2C9 Inhibitors.
    Nomoto M; Ferry J; Hussein Z
    J Clin Pharmacol; 2018 Dec; 58(12):1629-1638. PubMed ID: 29905956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis.
    Lu J; Jamieson BD; Hui AM
    Therap Adv Gastroenterol; 2022; 15():17562848221105976. PubMed ID: 35795378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombocytopenia and Hemostatic Changes in Acute and Chronic Liver Disease: Pathophysiology, Clinical and Laboratory Features, and Management.
    Scharf RE
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33917431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
    Aguilar C
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):231-6. PubMed ID: 23518832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombocytopenia in Chronic Liver Disease: Challenges and Treatment Strategies.
    Desai S; Subramanian A
    Cureus; 2021 Jul; 13(7):e16342. PubMed ID: 34277309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy of avatrombopag and recombinant human thrombopoietin in the treatment of chronic liver disease-associated severe thrombocytopenia: A real-world study.
    Wang YS; Wang W; Zhang S; Zhang SY; Shen AZ; Wang W; Song HC; Yao HZ; Song RP; Meng FZ; Li L; Nashan B; Wang JZ; Liu LX
    Front Pharmacol; 2022; 13():1009612. PubMed ID: 36267268
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures.
    Yoshiji H; Ueno Y; Kurosaki M; Torimura T; Hatano E; Yatsuhashi H; Yamakado K
    Hepatol Res; 2021 Dec; 51(12):1181-1195. PubMed ID: 34555262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.